Neuronal TGase (TG6) ELISA

ZediXclusive TG6-ab ELISA (IgG)


Neuronal transglutaminase (TG6) ELISA IgG

Order
Quantity
Price
Status
1 Kit/96 wells 520 € available


Documents
Art. No. E104
Background info The TG6-ab ELISA (IgG) kit with the Zedira product number E104 is the revised version of kit TG6-ab ELISA (IgG) with the product number E004.

Autoantibodies directed against neuronal transglutaminase (TG6) may occur in the sera of patients suffering from neurological disorders like e.g. ataxia, neuropathy, cerebral pulsy or stiffperson syndrome.
Autoantibodies to TG6 can be found in addition to TG2-autoantibodies in celiac patients, but were also found in TG2-autoantibody negative sera and in sera from patients without enteropathy (non-celiac patients). Therefore antibodies to TG6 may develop independent from celiac disease.
Assay principle The wells of the solid phase are coated with TG6.
1st reaction: TG6-specific antibodies present in the sample bind to the immobilised antigen, forming the antigen-antibody complex.
2nd reaction: A second antibody, directed at human IgG antibodies and labeled with horse-radish peroxidase (HRP), binds to the complex.
3rd reaction: The enzyme-labelled complex converts a substrate into a blue product. Samples containing IgG antibodies against TG6 develop the blue colour, whereas samples without these antibodies remain colourless.
Intended use The present Enzyme-Linked Immuno Sorbent Assay (ELISA) is intended for the quantitative or qualitative determination of IgG antibodies in human serum, directed against TG6. The immobilised antigen is a highly purified preparation of human recombinant TG6. The test is fast (incubation time 30 / 30 / 30 minutes) and flexible (divisible solid phase, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control check the assay performance.
Storage Store kit at 2 - 8°C. It is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • CELIACHIA 2020

    07.02.2020 - 08.02.2020
    Milan, Italy

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland